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Abstract
Background: Rhinitis is a very common disease with allergies being the most frequent causative factor. It can co-occur
together with asthma and eczema in atopic as well as in nonatopic patients.
Objectives: To assess the prevalence of allergic sensitization within patient groups with rhinitis in consideration of the co-
occurring disorders of asthma and eczema.
Methods: Students of the third year of medical school completed an anonymous questionnaire on age, gender, and clinical
symptoms, such as seasonal rhinitis, perennial rhinitis, asthma, and eczema, and underwent an ImmunoCAP Rapid test.
We calculated the prevalence of sensitization within subgroups of patients reporting allergic disorders, such as rhinitis,
asthma, and eczema.
Results: Questionnaires and ImmunoCAP Rapid tests of 1513 medical students were analyzed. The participants’ self-
reported presence of seasonal/perennial rhinitis, asthma, and eczema was compared to the presence of sensitization.
Data of 1467 subjects could be analyzed. Seasonal rhinitis was the most common symptom, followed by eczema, asthma,
and perennial rhinitis. The participants were differentiated into 16 subgroups according to the combined clinical manifes-
tations of the different symptoms and association to sensitization within subgroups. The prevalence of sensitization ranged
from 18% in subjects reporting only eczema without any other symptom to 100% in those reporting to have asthma,
seasonal/perennial rhinitis, and eczema together. In subjects reporting no sign or symptom at all, the prevalence of sensi-
tization was 19%. Seasonal rhinitis was the strongest single predictor for sensitization with the highest proportion of
sensitized participants in all symptom combinations (67%–100%), followed by perennial rhinitis (31%–100%), asthma
(30%–100%), and eczema (18%–100%).
Conclusion: Rhinitis most often is associated with allergen sensitization, and the probability of sensitization is substantially
enhanced by co-occurrence of asthma. A careful assessment of clinical signs and symptoms is important and enables the
selection of patients in whom targeted diagnostic analysis and therapy is appropriate.
Trial registration: retrospectively registered by the Cantonal Ethics Committee Zurich on 22.01.2016; Nr: 08-2016.
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Introduction
Rhinitis is a common chronic disorder, which is com-
monly divided into allergic and nonallergic rhinitis
with a prevalence of about 30% and 10%, respective-
ly.1–4 While allergic rhinitis is associated with defined
allergic trigger factors and specific IgE antibodies, non-
allergic rhinitis includes vasomotor, occupational,
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hormonal, atrophic, iatrogenic, idiopathic, or infectious
entities.4–7 The similar phenotype of different underlying
endotypes of rhinitis makes a timely diagnosis and spe-
cific therapy often difficult. This might explain why in
35% to 40% of patients with rhinitis the disease is not
controlled, which results in elevated medical and socio-
economic costs.8–15 Rhinitis often co-occurs with asthma
and eczema and is often associated with atopy. But these
allergic disorders also co-occur in nonatopic patients
more often than can be expected to happen by
chance.16,17 A clinician should aim to distinguish allergic
versus nonallergic rhinitis early as there are different
treatment options available. For this study, we evaluated
a selected, homogeneous population of 1683 Swiss med-
ical students with an accumulation of risk factors for
allergic disorders including higher socioeconomic
status, completion of higher education, and urban life
style.18–20
We sought to determine whether a thorough patient
history including the clinical manifestations of rhinitis,
asthma, and eczema helps to differentiate allergic rhinitis
from nonallergic rhinitis. We assessed the prevalence of
allergen sensitization according to the co-occurrence of
the clinical manifestations of rhinitis, asthma,
and eczema.
Materials and Methods
The local Ethical Review Board of Zurich assessed the
protocol of this study and offered a waiver (#8-2016).
The study strictly adhered to the principles of good clin-
ical practice and the ethical standards outlined in the
Declaration of Helsinki.21 The reporting guidelines for
observational studies (STROBE) were applied.22
Participants
From 2007 to 2015, all third-year medical students at the
University of Zurich who attended the practical course
in immunology were included, forming 9 annual cohorts.
No exclusion criteria were imposed. In Switzerland,
medical students usually study for 6 years after complet-
ing secondary school at an age of 18 years on average.
Zurich University has the largest medical school in
Switzerland, with about 220 students per clinical year.
About 10% of students are from abroad. The number of
inhabitants living in the catchment area for medical stu-
dents at the University of Zurich is approximately 3 mil-
lion. This corresponds to about 40% of the Swiss
population. The proportion of female students has
steadily increased and surpassed the 50% margin
in 2009.
Data collection
We secured information from a self-reported question-
naire on age, gender, and occurrence of seasonal or
perennial rhinitis, asthma, and eczema from all
participants.
Each student tested his or her blood during the prac-
tical course in immunology, using the ImmunoCAP
Rapid test kit, a qualitative point-of-care test (Thermo
Fisher Scientific Inc, Waltham, MA) according to the
manufacturer’s instructions and watching a short film
sequence (http://www.phadia.com/en/Products/Allergy-
testing-products/ImmunoCAP-Rapid). In addition,
senior staff of the University Clinic for Immunology
supervised testing. We entered anonymized personal
data and the results from blood tests into an electronic
database for statistical analysis.
Specific IgE antibodies against the 10 common aero-
allergens, cat dander (e1), birch (t3, Betula verrucosa),
mugwort (w6, Artemisia vulgaris), timothy grass (g6,
Phleum pratense), cockroach (i6, Blatella germanica),
dog dander (e5), olive (t9, Olea europaea), wall pellitory
(w21, Parietaria judaica), house dust mite (d1,
Dermatophagoides pteronyssinus), and mold (m6,
Alternaria alternata) were measured. The 2007 test
(ImmunoCAP Rapid wheeze/rhinitis child) contained
egg white (f1) and cow’s milk (f2) instead of cockroach
and mold.
All participants were verbally informed and gave their
oral informed consent in handing in the questionnaire
and the test results.
Definitions
We defined atopy as a sensitization to any of the tested
allergens. Sensitization to olive pollen was interpreted as
a sensitization to ash pollen due to a cross-reaction of
the specific IgE antibodies.23
The occurrence of atopic diseases, namely rhinitis,
asthma, and eczema, was assessed by self-reported
answers to the questions: “Do you suffer from season-
al/perennial rhinitis, asthma or eczema?” We postulated
that third-year medical students have the necessary med-
ical knowledge to answer these questions.
Subgroups According to Clinical Symptoms
and State of Sensitization
We defined 16 different subgroups reflecting all possible
combinations of the different clinical phenotypes con-
sisting of seasonal and perennial rhinitis, asthma,
and eczema. Association to sensitization was evaluated
for each subgroup.
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Statistical Analysis
Interval scaled variates were summarized with means
and standard deviations or medians and interquartile
ranges (IQRs), where appropriate. Dichotomous vari-
ates were described as ratios and percentages. We per-
formed all analyses using the Stata 14.2 statistics
software package (StataCorp LP, College Station, TX)
Results
From 1683 third-year medical students assessed between
2007 and 2015, the ImmunoCAP Rapid test results were
available in 1513 participants (Figure 1). The median
cohort size across annual courses was 215 students,
(IQR: 193–222) and the proportion of female students
ranged from 43% to 62%. The mean age ranged from
22.4 years to 23.3 years. Overall sensitization was 40%
(604 of 1513). Sensitization to grass pollen was most
prevalent followed by birch pollen and house dust
mites (Table 1).
Sensitization rate and clinical data on rhinitis,
asthma, and eczema were available in 1467 subjects
(Figure 1). Seasonal rhinitis was the most prevalent
symptom in 546 (37%) subjects followed by eczema,
asthma, and perennial rhinitis. Comparing atopic with
nonatopic subjects, all symptoms except for eczema were
more prevalent in atopics (Table 2).
Subgroup Analysis
The prevalence of sensitization within subgroups suffer-
ing from single symptoms ranged from 18% (17 of 95) in
subjects reporting only eczema, to 30% (10 of 33) with
asthma, to 30% (8 of 26) with perennial rhinitis, and to
68% (228 of 335) with seasonal rhinitis. In subjects with
co-occurrence of 2 allergic disorders, a sensitization rate
of 76% (142 of 186) was documented. In participants
with perennial or seasonal rhinitis and asthma sensitiza-
tion rate was 60% (6 of 10) and 84% (62 of 74), with
perennial or seasonal rhinitis and eczema 67% (4 of 6)
and 71% (48 of 68), with seasonal and perennial rhinitis
89% (17 of 19) and with asthma and eczema 55% (5
1683 subjects were included
1513 were analyzed for their sensitization by 
ImmunoCAP Rapid test 
1467 were analyzed for the relation 
between rhinitis, asthma, eczema 
and sensitization 
170 did not perform ImmunoCAP Rapid test
46 did not complete questionnaire correctly
26 missing for eczema
16 missing for rhinitis
4 missing for asthma
Figure 1. Included and analyzed participants.
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of 9), respectively. Sensitization rate in participants with
3 allergic disorders was 78% (185 of 237). Seasonal and
perennial rhinitis with eczema or asthma were sensitized
in 67% (4 of 6) and 85% (11 of 13), and asthma and
eczema with seasonal or perennial rhinitis in 89% (25 of
28) and 100% (1 of 1), respectively. Highest sensitization
rate was assessed in subjects reporting to have seasonal/
perennial rhinitis, asthma, and eczema together with
100% (3 of 3). In subjects reporting no sign or symptom
at all, the prevalence of sensitization was 19% (140
of 741).
From the investigated population, 49% (726 of 1467)
suffered from at least 1 allergic disorder and 16% (237 of
1467) from at least 2 or 3 allergic disorders. Rhinitis co-
occurred more often together with asthma than with
eczema. Prevalence of sensitization across all subgroups
with the combination of the different comorbidities is
shown in Table 3.
Discussion
In this study, we analyzed the sensitization rate and co-
occurrence of the allergic disorders rhinitis, asthma, and
eczema in a large cohort of Swiss medical students. The
documented sensitization rate of 40% corresponds with
previously published data from industrialized coun-
tries.24–26 Grass pollen was the most frequently detected
allergen followed by house dust mites and tree pollen
which is in line with other studies.24,25 Although this
well-educated study population in particular living in
urban environment has an increased risk to suffer from
allergies,18–20 the prevalence of atopic disorders was
comparable with the current literature in which different
risk profiles were not addressed. Recent evidence sug-
gests that rhinitis, asthma, and eczema are coexisting
disorders becoming more prevalent with increasing
age.16,27 They are strongly associated with specific IgE
antibodies but also co-occur in nonsensitized individu-
als.17,28 Seasonal rhinitis is the most common symptom
of these allergic disorders in atopic and nonatopic
subjects with a prevalence of 10% to 30%. Comparing
seasonal and perennial rhinitis, the former is clearly
more associated with atopy (Tables 2 and 3).3,4,17,27,29
The prevalence of the allergic disorders in our cohort
for allergic seasonal rhinitis with 27%, allergic asthma
with 8%, and atopic eczema 7% is in line with the cur-
rent literature (Table 2).27,30–33
The strongest single predictor for allergen sensitiza-
tion was seasonal rhinitis (68%), and the probability of
Table 2. Comorbidities With the Individual Ratio of Atopic and
Nonatopic Subjects (N¼ 1467).
All Atopic Nonatopic
Seasonal rhinitis 546 (37%) 398 (73%) 148 (27%)
Perennial rhinitis 84 (6%) 53 (63%) 31 (37%)
Asthma 161 (11%) 117 (72%) 44 (28%)
Eczema 216 (15%) 106 (49%) 110 (51%)
Table 1. Characteristics of the 9 Study Cohorts From 2007
to 2017.
Parameter Frequency
Cohort size 2007–2015 1513
Median cohort size 215 (IQR: 192–222)
Female subjects 44%–62%
Mean age, years 22.4–23.3
Frequency of sensitization
Sensitization 604 (40%)
Cat dander (e1) 106 (7%)
Birch (t3) 231 (15%)
Mugwort (w6) 42 (3%)
Timothy grass (g6) 416 (27%)
Cockroach (i6) 17 (1%)
Dog dander (e5) 25 (2%)
Olive (t9) 179 (12%)
Parietaria (w21) 29 (2%)
House dust mite (d1) 265 (17%)
Mold (Alternaria, m6) 28 (2%)
Abbreviation: IQR: interquartile range.
Sensitization measured by ImmunoCAP Rapid test.
Table 3. Subgroup Analysis of Combined Occurrence of Allergic Disorders (N¼ 1467).
Perennial Rhinitis
No Yes
Seasonal Rhinitis Seasonal Rhinitis
No Yes No Yes
Asthma No Eczema No 741 (19%) 335 (68%) 26 (30%) 19 (89%)
Yes 95 (18%) 68 (71%) 6 (50%) 6 (67%)
Yes Eczema No 33 (30%) 74 (84%) 10 (60%) 13 (85%)
Yes 9 (55%) 28 (89%) 1 (100%) 3 (100%)
Values in parenthesis represent the number of sensitized participants.
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sensitization is enhanced when additional symptoms
with perennial rhinitis and asthma co-occur. However,
eczema was a weak predictor for sensitization (Table 3).
This is most probably explained by the sensitization path
occurring more often by inhalant allergens via the respi-
ratory tract mucosa and not via the skin.34
The lack of detailed information about the subjects’
genetic background, place of birth, and the time point
when sensitization and/or allergic symptoms were first
diagnosed is a potential limitation of this study. Self-
reporting of symptoms carries the risk of reporting
bias. The possibility of a different understanding of
how to make a diagnosis of rhinitis, asthma, and
eczema is a potential limitation, and we cannot fully
rule out that such bias occurred in our study. On the
other hand, it can be expected that third-year medical
students have the necessary medical knowledge to indi-
cate whether they are suffering from seasonal/perennial
rhinitis, asthma, or eczema.
In conclusion, patients with rhinitis have a high prob-
ability of suffering from allergies. Co-occurrence of
asthma enhances this probability substantially. In all
patients with rhinitis as a single clinical symptom or
combined with asthma and/or eczema an allergologic
workup is reasonable. This enables an early and targeted
therapy.
Ethical Approval
The local Ethical Review Board of Zurich assessed the protocol
of this study and offered a waiver (#8-2016).
Statement of Human and Animal Rights
The study strictly adhered to the principles of good clinical
practice and the ethical standards outlined in the Declaration
of Helsinki. The reporting guidelines for observational studies
(STROBE) were applied.
Statement of Informed Consent
All participants were verbally informed and gave their oral
informed consent in handing in the questionnaire and the
test results.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of
this article.
Funding
The author(s) received no financial support for the research,
authorship, and/or publication of this article.
References
1. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phe-
notypes of chronic rhinosinusitis: a PRACTALL
document of the European Academy of Allergy and
Clinical Immunology and the American Academy of
Allergy, Asthma & Immunology. J Allergy Clin Immunol.
2013;131(6):1479–1490.
2. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic
rhinosinusitis. World Allergy Organ J. 2014;7(1):25.
3. Hamilos DL. Chronic rhinosinusitis: epidemiology and
medical management. J Allergy Clin Immunol.
2011;128(4):693–707; quiz 8–9.
4. Katelaris CH, Lee BW, Potter PC, et al. Prevalence and
diversity of allergic rhinitis in regions of the world beyond
Europe and North America. Clin Exp Allergy.
2012;42(2):186–207.
5. Rondon C, Romero JJ, Lopez S, et al. Local IgE produc-
tion and positive nasal provocation test in patients with
persistent nonallergic rhinitis. J Allergy Clin Immunol.
2007;119(4):899–905.
6. Poddighe D, Gelardi M, Licari A, Del Giudice MM,
Marseglia GL. Non-allergic rhinitis in children: epidemio-
logical aspects, pathological features, diagnostic methodol-
ogy and clinical management. World J Methodol.
2016;6(4):200–213.
7. Bose S, Grammer LC, Peters AT. Infectious chronic rhi-
nosinusitis. J Allergy Clin Immunol Pract.
2016;4(4):584–589.
8. Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled
allergic rhinitis and chronic rhinosinusitis: where do we
stand today? Allergy. 2013;68(1):1–7.
9. van Cauwenberge P, Bachert C, Passalacqua G, et al.
Consensus statement on the treatment of allergic rhinitis.
European Academy of Allergology and Clinical
Immunology. Allergy. 2000;55(2):116–134.
10. Schoenwetter WF, Dupclay L Jr, Appajosyula S,
Botteman MF, Pashos CL. Economic impact and
quality-of-life burden of allergic rhinitis. Curr Med Res
Opin. 2004;20(3):305–317.
11. Settipane RA, Charnock DR. Epidemiology of rhinitis:
allergic and nonallergic. Clin Allergy
Immunol. 2007;19:23–34.
12. Blaiss MS. Allergic rhinitis: direct and indirect costs.
Allergy Asthma Proc. 2010;31(5):375–380.
13. Tran NP, Vickery J, Blaiss MS. Management of rhinitis:
allergic and non-allergic. Allergy Asthma Immunol Res.
2011;3(3):148–156.
14. Cazzoletti L, Ferrari M, Olivieri M, et al. The gender, age
and risk factor distribution differs in self-reported allergic
and non-allergic rhinitis: a cross-sectional population-
based study. Allergy Asthma Clin Immunol. 2015;11:36.
15. Belhassen M, Demoly P, Bloch-Morot E, et al. Costs of
perennial allergic rhinitis and allergic asthma increase with
severity and poor disease control. Allergy.
2017;72:948–958.
16. Aguilar D, PinartM,KoppelmanGH, et al. Computational
analysis ofmultimorbidity between asthma, eczema and rhi-
nitis. PLoS One. 2017;12(6):e0179125.
17. Pinart M, Benet M, Annesi-Maesano I, et al. Comorbidity
of eczema, rhinitis, and asthma in IgE-sensitised and non-
IgE-sensitised children in MeDALL: a population-based
cohort study. Lancet Respir Med. 2014;2(2):131–140.
Steiner et al. 5
18. Schafer T, Ruhdorfer S, Weigl L, et al. School education
and allergic sensitization in adults. Allergy.
2001;56(12):1206–1210.
19. D’Amato G, Cecchi L, D’Amato M, Liccardi G. Urban air
pollution and climate change as environmental risk factors
of respiratory allergy: an update. J Investig Allergol Clin
Immunol. 2010;20(2):95–102; quiz following 102.
20. Bergmann KC, Heinrich J, Niemann H. Current status of
allergy prevalence in Germany: position paper of the
Environmental Medicine Commission of the Robert
Koch Institute. Allergo J Int. 2016;25:6–10.
21. World Medical Association Declaration of Helsinki: ethi-
cal principles for medical research involving human sub-
jects. J Am Coll Dent. 2014;81(3):14–18.
22. Cevallos M, Poole C, von Elm E, Altman D, Egger M.
Response to Rezaeian: strengthening the reporting of
observational studies in epidemiology (STROBE) exten-
sion for ecological studies. J Clin Epidemiol.
2014;67(7):837–838.
23. Imhof K, Probst E, Seifert B, Regenass S, Schmid-
Grendelmeier P. Ash pollen allergy: reliable detection of
sensitization on the basis of IgE to Ole e 1. Allergo J Int.
2014;23(3):78–83.
24. Wuthrich B, Schindler C, Leuenberger P, Ackermann-
Liebrich U. Prevalence of atopy and pollinosis in the
adult population of Switzerland (SAPALDIA study).
Swiss Study on Air Pollution and Lung Diseases in
Adults. Int Arch Allergy Immunol. 1995;106(2):149–156.
25. Haftenberger M, Laussmann D, Ellert U, et al.
[Prevalence of sensitisation to aeraoallergens
and food allergens: results of the German Health
Interview and Examination Survey for Adults
(DEGS1)]. Bundesgesundheitsblatt, Gesundheitsforschung,
Gesundheitsschutz. 2013;56(5–6):687–697.
26. Salo PM, Arbes SJ Jr, Jaramillo R, et al. Prevalence of
allergic sensitization in the United States: results from
the National Health and Nutrition Examination Survey
(NHANES) 2005-2006. J Allergy Clin Immunol.
2014;134(2):350–359.
27. Gough H, Grabenhenrich L, Reich A, et al. Allergic multi-
morbidity of asthma, rhinitis and eczema over 20 years in
the German birth cohort MAS. Pediatr Allergy Immunol.
2015;26(5):431–437.
28. Garcia-Aymerich J, Benet M, Saeys Y, et al. Phenotyping
asthma, rhinitis and eczema in MeDALL population-
based birth cohorts: an allergic comorbidity cluster.
Allergy. 2015;70(8):973–984.
29. Ballardini N, Kull I, Lind T, et al. Development and
comorbidity of eczema, asthma and rhinitis to age 12:
data from the BAMSE birth cohort. Allergy.
2012;67(4):537–544.
30. Del Giacco SR, Bakirtas A, Bel E, et al. Allergy in severe
asthma. Allergy. 2017;72(2):207–220.
31. Simpson BM, Custovic A, Simpson A, et al. NAC
Manchester Asthma and Allergy Study (NACMAAS):
risk factors for asthma and allergic disorders in adults.
Clin Exp Allergy. 2001;31(3):391–399.
32. Silverberg JI, Hanifin JM. Adult eczema prevalence and
associations with asthma and other health and demograph-
ic factors: a US population-based study. J Allergy Clin
Immunol. 2013;132(5):1132–1138.
33. Weidinger S, Novak N. Atopic dermatitis. Lancet (London,
England). 2016;387(10023):1109–1122.
34. Scadding GK, Bousquet J. Introduction: allergic rhinitis.
Allergy. 2007;62 Suppl 85:3–5.
6 Allergy & Rhinology
